Quick Answer
Forte Biosciences, Inc. reported Long Term Debt of $26.20 million for the year ending 2018.
- Forte Biosciences, Inc. showed an increase of +622.8% in Long Term Debt from 2017 to 2018.
- This data is from Forte Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2020.
- XBRL data for this metric is available from 2016 to 2018 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $8.58 million | Q2 2017: $6.93 million | Q3 2017: $5.28 million | Q1 2018: $1.97 million | Q2 2018: $25.91 million | Q3 2018: $26.06 million | Q1 2019: $24.14 million | Q2 2019: $22.08 million.
- Over the full 3 years of available data (2016 to 2018), Forte Biosciences, Inc.'s Long Term Debt has grown by 155.8%.
- Historical annual values: Fiscal year 2018: $26.20 million | Fiscal year 2017: $3.63 million | Fiscal year 2016: $10.24 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: